Best Practices and Research Advances in Thoracic Oncology: A Regional Series Eastern Europe/Baltic Course 3: Driver Alterations in Lung Cancer-Adjuvant Treatment from EGFR to Other Targets

Adjuvant Treatment from EGFR to Other Targets

Video Transcription

Video Summary

Dr. Alon Azer, a medical oncologist, discussed targeted therapies for early-stage and locally advanced non-small cell lung cancer (NSCLC) in a webinar featuring experts from Eastern Europe, the Balkans, and Israel. Targeted therapies have improved treatment of advanced cases, but challenges remain for early stages. EGFR and ALK alterations, though less frequent in early stages, worsen lung cancer prognosis. Data from studies like ADAURA support osimertinib in resected EGFR-mutated NSCLC, showing improved survival. Additionally, alectinib has shown promise for ALK-positive cases. Ongoing research explores optimal durations and responses to therapies.

Asset Subtitle

Alona Zer, MD

Keywords

targeted therapies

non-small cell lung cancer

EGFR mutations

osimertinib

ALK-positive